Dan Larson overcame lung cancer through robotic-assisted surgeries, highlighting Intuitive's innovative technology in patient care.
Quiver AI Summary
Dan Larson, a Seattle resident diagnosed with lung cancer in 2023, benefited from robotic-assisted surgery developed by Intuitive, a leader in robotic surgical technology. After undergoing two robotic lung biopsies using the Ion Endoluminal System and a robotic lobectomy with the da Vinci 5 system at MultiCare Tacoma General Hospital, Dan achieved a successful recovery. He and his physicians were invited to Intuitive's facility to celebrate the company's 30th anniversary and share his journey, highlighting the importance of proactive health checks and advanced medical technology. Dan's doctors emphasized the transformative impact these robotic systems had on his treatment and recovery. In addition, Intuitive employees participated in a wellness challenge to raise $25,000 for St. Jude Children's Research Hospital in honor of Dan and his wife, Cindy.
Potential Positives
- Dan Larson's successful treatment through Intuitive's robotic technology highlights the effectiveness and impact of the company's innovations in improving patient outcomes in lung cancer care.
- The press release commemorates Intuitive's 30 years of dedication to advancing robotic-assisted surgery, reinforcing its position as a leader in the field.
- The connection made between patients like Dan, healthcare providers, and Intuitive employees emphasizes the company's commitment to patient-centered care and showcases real-world applications of its technology.
- The collaboration with the Intuitive Foundation to raise $25,000 for St. Jude Children's Research Hospital promotes corporate social responsibility and enhances the company's image in the community.
Potential Negatives
- Serious complications may occur in any surgery, including those using the da Vinci system, with risks as severe as death, emphasizing inherent dangers associated with the technology.
- The safety and effectiveness evaluation for the da Vinci 5 system did not assess outcomes specifically related to cancer treatment, raising concerns about the technology's reliability in this critical area.
- The press release may inadvertently highlight the severity of cancer diagnoses and treatments, which could raise questions about the prevalence and management of such conditions in patients using the company’s technology.
FAQ
What innovative technology did Dan Larson use for his lung cancer treatment?
Dan Larson utilized Intuitive's Ion Endoluminal System and da Vinci 5 robotic surgery system for his lung cancer treatment.
How did robotic surgery impact Dan's recovery?
Robotic surgery allowed Dan to have less invasive procedures and a quicker recovery, returning home within 48 hours post-lobectomy.
What role did his healthcare providers play in his treatment?
Dr. Abhishek Biswas performed vital biopsies, while Dr. Baiya Krishnadasan successfully executed the lobectomy using the da Vinci 5 system.
What is the significance of Intuitive's 30th anniversary?
Intuitive's 30th anniversary highlights its commitment to innovating robotic-assisted technology to improve patient outcomes and surgical experiences.
How has Intuitive contributed to charitable causes?
Intuitive raised $25,000 for St. Jude Children's Research Hospital as part of an internal wellness challenge, reflecting its community commitment.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ISRG Insider Trading Activity
$ISRG insiders have traded $ISRG stock on the open market 72 times in the past 6 months. Of those trades, 0 have been purchases and 72 have been sales.
Here’s a breakdown of recent trading of $ISRG stock by insiders over the last 6 months:
- DAVID J. ROSA (President) has made 0 purchases and 2 sales selling 16,509 shares for an estimated $9,204,142.
- ROBERT DESANTIS (EVP & Chief Strategy & Corp Op) has made 0 purchases and 18 sales selling 13,307 shares for an estimated $6,689,314.
- BRIAN EDWARD MILLER (EVP & Chief Digital Officer) has made 0 purchases and 5 sales selling 12,900 shares for an estimated $6,365,341.
- MYRIAM CURET (EVP & Chief Medical Officer) has made 0 purchases and 4 sales selling 9,840 shares for an estimated $5,438,101.
- JAMIE SAMATH (See Remarks) has made 0 purchases and 21 sales selling 9,028 shares for an estimated $5,123,629.
- AMY L LADD has made 0 purchases and 6 sales selling 8,926 shares for an estimated $4,521,660.
- AMAL M JOHNSON sold 4,635 shares for an estimated $2,626,191
- GARY LOEB (EVP & Chief Legal and Complian) has made 0 purchases and 3 sales selling 4,300 shares for an estimated $2,390,260.
- MARK BROSIUS (SVP & Chief Mfg and Supply Cha) has made 0 purchases and 10 sales selling 2,565 shares for an estimated $1,428,497.
- JAMI K NACHTSHEIM sold 2,400 shares for an estimated $1,248,000
- FREDRIK WIDMAN (VP Corporate Controller) sold 810 shares for an estimated $464,761
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ISRG Hedge Fund Activity
We have seen 1,133 institutional investors add shares of $ISRG stock to their portfolio, and 900 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO removed 1,576,385 shares (-15.5%) from their portfolio in Q1 2025, for an estimated $780,736,198
- GQG PARTNERS LLC removed 1,145,300 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $567,232,731
- FMR LLC removed 1,089,681 shares (-10.1%) from their portfolio in Q1 2025, for an estimated $539,686,308
- PROFICIO CAPITAL PARTNERS LLC removed 948,095 shares (-99.8%) from their portfolio in Q1 2025, for an estimated $469,563,010
- FISHER ASSET MANAGEMENT, LLC removed 821,665 shares (-16.9%) from their portfolio in Q1 2025, for an estimated $406,946,024
- PRICE T ROWE ASSOCIATES INC /MD/ removed 686,369 shares (-4.7%) from their portfolio in Q1 2025, for an estimated $339,937,974
- BAILLIE GIFFORD & CO removed 608,415 shares (-16.1%) from their portfolio in Q1 2025, for an estimated $301,329,697
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ISRG Analyst Ratings
Wall Street analysts have issued reports on $ISRG in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 05/22/2025
- Piper Sandler issued a "Overweight" rating on 04/23/2025
- BTIG issued a "Buy" rating on 04/14/2025
- UBS issued a "Overweight" rating on 01/29/2025
- Morgan Stanley issued a "Overweight" rating on 01/16/2025
- Bernstein issued a "Outperform" rating on 01/08/2025
To track analyst ratings and price targets for $ISRG, check out Quiver Quantitative's $ISRG forecast page.
$ISRG Price Targets
Multiple analysts have issued price targets for $ISRG recently. We have seen 4 analysts offer price targets for $ISRG in the last 6 months, with a median target of $622.5.
Here are some recent targets:
- Ryan Zimmerman from BTIG set a target price of $560.0 on 04/14/2025
- An analyst from Truist Financial set a target price of $605.0 on 03/17/2025
- Patrick Wood from Morgan Stanley set a target price of $650.0 on 12/02/2024
Full Release
SUNNYVALE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- When Seattle resident Dan Larson was diagnosed with lung cancer in 2023, his only exposure to robotic technology was through his work as a quality engineer at Boeing. He could never have imagined that robotic technology made by Intuitive, the pioneer of robotic-assisted surgery, would one day play a pivotal role in his health care.
Having experienced the loss of his father to lung cancer, Dan was determined to overcome his own diagnosis and enjoy his retirement with his family. Under the care of clinicians at MultiCare Tacoma General Hospital in Washington, Dan underwent two robotic lung biopsies with the Ion Endoluminal System, Intuitive’s robotic-assisted bronchoscopy platform, followed by a robotic-assisted lobectomy—removal of part of the lung— with the da Vinci 5 system, Intuitive’s next-generation multiport robotic system.
Following his successful procedures, Intuitive invited Dan and his wife Cindy, and his physicians, Abhishek Biswas, MD and Baiya Krishnadasan, MD, FACS, both from Tacoma General, to join the engineers, manufacturers, and other Intuitive employees who designed the technology that helped change his life to share his story as the company marks 30 years since its founding.
“When you’ve seen a loved one go through what I saw my father go through, you’re willing to do anything if it means you will get better. I was lucky to have experienced doctors with the best technology near me, and from New Year’s Eve to today, it’s been a great recovery,” said Dan.
“To other people who may think they’re in a similar situation, don’t wait to get checked, get your answers, and have it taken care of,” said Dan.
Dan spent his career dedicated to quality as a quality assurance investigator at Boeing, so the opportunity to see a behind-the-scenes manufacturing tour at Intuitive was especially meaningful. He witnessed the precision and dedication that goes into building the Ion and da Vinci systems, the technologies used in his care.
Dr. Abhishek Biswas, who performed Dan’s two Ion biopsies - one that resulted in a diagnosis in 2023 and then to detect local recurrence in 2024 - demonstrated the system to Dan and showed him the 3D navigation path of his own lungs that Dr. Biswas used for guidance when navigating to his target lung nodule.
“Dan was one of the first 25 patients I was able to biopsy with Ion, and without it, his cancer could have progressed to stage four. This technology is truly transformative. Thank you to Intuitive for developing something that is uniquely different and that has made a huge impact on my work, so I can do what is right for my patient,” said Biswas, interventional pulmonologist at MultiCare.
Once Dan’s lung cancer had been diagnosed, Dr. Baiya Krishnadasan, cardiothoracic surgeon at MultiCare, used the da Vinci 5 system to remove part of his lung on New Year's Eve 2024.
"Dan's case is truly heartwarming and special. This was a very complex procedure with a high risk of complications, but with the use of the da Vinci 5 system, we performed a successful operation, and he was able to return home within 48 hours. His positive attitude is inspiring, and it's gratifying to see how well he's done. I'm excited to teach others how to use this remarkable technology," said Krishnadasan.
MultiCare Health System was one of the first health systems in the Pacific Northwest to install a da Vinci 5 system. MultiCare has 30 da Vinci systems across various sites, including four da Vinci 5’s, as well as four Ion Endoluminal Systems.
“Dan's story is powerful evidence of Intuitive’s 30-year mission of putting patients first,” said Intuitive President Dave Rosa.
“Each day at Intuitive, we strive to solve hard problems so that clinicians can provide better outcomes for their patients. It was an honor to have Dan, his wife Cindy, and his physicians meet our teams to reinforce the connection between our employees and the patients that are taken care of using our technology,” said Rosa.
2025 marks Intuitive’s 30th year developing robotic-assisted technology with the goal of improving patient outcomes, improving patient and care team experience, increasing access to minimally invasive care, and lowering the total cost to treat. In Intuitive's first three decades, surgeons performed nearly 17 million da Vinci procedures, and nearly 90,000 surgeons have been trained to use Intuitive’s systems.
To mark Dan's visit, Intuitive employees united to complete an internal Impact Wellness Challenge in collaboration with the Intuitive Foundation, raising $25,000. This amount will be donated by the Intuitive Foundation to St. Jude Children's Research Hospital, a charity chosen by Dan and his wife Cindy.
Contact: Peper Long, Intuitive
[email protected]
1-202-997-7373
About Intuitive
Intuitive (NASDAQ: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most.
About Ion
Ion is Intuitive’s robotic-assisted platform for minimally invasive biopsy in the lung. The system features an ultra-thin, ultra-maneuverable catheter that allows navigation far into the peripheral lung and provides the unprecedented stability necessary for precision in biopsy.
About da Vinci Surgical Systems
There are several models of the da Vinci Surgical System. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery and offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.
Important Safety Information
Patients should talk to their doctor to decide if surgery with a da Vinci system is right for them. Patients and doctors should review all available information on nonsurgical and surgical options and associated risks in order to make an informed decision.
Serious complications may occur in any surgery, including surgery with a da Vinci system, up to and including death. For important safety information, including surgical risks and considerations, please refer to intuitive.com/safety.
For product intended use and/or indications for use, risks, cautions, and warnings and full prescribing information, refer to the associated user manual(s) or visit https://manuals.intuitivesurgical.com/market.
The demonstration of safety and effectiveness for the representative-specific procedures was based on evaluation of the da Vinci 5 system as a surgical tool and did not include evaluation of outcomes related to the treatment of cancer (overall survival, disease-free survival, local recurrence) or treatment of the patient’s underlying disease or condition. Device usage in all surgical procedures should be guided by the clinical judgment of an adequately trained surgeon.
Individuals’ outcomes may depend on a number of factors—including but not limited to—patient characteristics, disease characteristics, and/or surgeon experience.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/ff6785f3-8909-444d-a5e1-12e01a6e9935
https://www.globenewswire.com/NewsRoom/AttachmentNg/4ebd5e5f-cb49-41d4-9117-1c2dfb72e5dc
https://www.globenewswire.com/NewsRoom/AttachmentNg/ca25e383-910f-4b43-8e31-3bff3231e7df
https://www.globenewswire.com/NewsRoom/AttachmentNg/6354a798-8bb4-47dc-a4ad-b845d321d637
https://www.globenewswire.com/NewsRoom/AttachmentNg/6c54d527-8777-4581-aa46-2e24eb11c9f3